Literature DB >> 29660762

A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms.

Seyed Ehsan Alavian1,2, Heidar Sharafi1,2, Paniz Shirmast2, Seyed Moayed Alavian1, Bita Behnava1, Mohammad Pouryasin3, Maryam Keshvari4, Ali Pouryasin3.   

Abstract

BACKGROUND: Inosine triphosphate pyrophosphatase (ITPA) gene single nucleotide polymorphisms (SNPs), rs1127354 and rs7270101, may cause a functional impairment in ITPase enzyme, resulting anemia protection in patients with chronic hepatitis C virus (HCV) infection undergoing ribavirin (RBV)-dependent regimens. The main purpose of this study was to provide and validate a simple, rapid, and inexpensive polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique for genotyping of ITPA rs1127354 and rs7270101 polymorphisms in chronic HCV-infected patients.
METHODS: In the current study, 100 Iranian patients with chronic hepatitis C were examined and genotyped for ITPA rs1127354 and rs7270101 gene polymorphisms. To genotype rs1127354 and rs7270101 polymorphisms, PCR-RFLP technique and sequencing technique were performed on these samples. To validate the PCR-RFLP method, the PCR-RFLP genotyping results should be 100% concordant with the PCR-sequencing results.
RESULTS: The rs1127354 and rs7270101 polymorphisms of ITPA gene were genotyped by PCR-RFLP technique and sequencing simultaneously, and the results of both techniques were 100% concordant in all 100 patients. Both PCR-RFLP and sequencing techniques indicated that the genotypic frequency of rs7270101 was 80% AA, 19% AC and 1% CC, and for rs1127354 was 79% CC, 20% CA and 1% AA, respectively.
CONCLUSION: We developed and validated a rapid and inexpensive PCR-RFLP technique for the detection of ITPA rs1127354 and rs7270101 gene polymorphisms.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  hepatitis C virus; inosine triphosphate pyrophosphatase gene; polymerase chain reaction; restriction fragment length polymorphism; sequencing; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2018        PMID: 29660762      PMCID: PMC6816863          DOI: 10.1002/jcla.22440

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  29 in total

1.  Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene.

Authors:  S Lin; A G McLennan; K Ying; Z Wang; S Gu; H Jin; C Wu; W Liu; Y Yuan; R Tang; Y Xie; Y Mao
Journal:  J Biol Chem       Date:  2001-03-13       Impact factor: 5.157

Review 2.  Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.

Authors:  Jan Paeshuyse; Kai Dallmeier; Johan Neyts
Journal:  Curr Opin Virol       Date:  2011-11-29       Impact factor: 7.090

3.  Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.

Authors:  Maryam Keshvari; Seyed Moayed Alavian; Bita Behnava; Ali Pouryasin; Johanna C Craig; Heidar Sharafi
Journal:  J Clin Lab Anal       Date:  2016-10-13       Impact factor: 2.352

4.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Authors:  Alexander J Thompson; Jacques Fellay; Keyur Patel; Hans L Tillmann; Susanna Naggie; Dongliang Ge; Thomas J Urban; Kevin V Shianna; Andrew J Muir; Michael W Fried; Nezam H Afdhal; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-06-12       Impact factor: 22.682

5.  Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

Authors:  Yuki Hitomi; Elizabeth T Cirulli; Jacques Fellay; John G McHutchison; Alexander J Thompson; Curtis E Gumbs; Kevin V Shianna; Thomas J Urban; David B Goldstein
Journal:  Gastroenterology       Date:  2011-01-01       Impact factor: 22.682

6.  ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin.

Authors:  Miyako Murakawa; Yasuhiro Asahina; Hiroko Nagata; Mina Nakagawa; Sei Kakinuma; Sayuri Nitta; Fukiko Kawai-Kitahata; Satoshi Otani; Shun Kaneko; Masato Miyoshi; Tomoyuki Tsunoda; Yu Asano; Ayako Sato; Yasuhiro Itsui; Seishin Azuma; Toshihiko Nouchi; Yohei Furumoto; Tooru Asano; Yoshimichi Chuganji; Shuji Tohda; Mamoru Watanabe
Journal:  Hepatol Res       Date:  2017-03-07       Impact factor: 4.288

7.  Substrate specificity of RdgB protein, a deoxyribonucleoside triphosphate pyrophosphohydrolase.

Authors:  Nicholas E Burgis; Richard P Cunningham
Journal:  J Biol Chem       Date:  2006-11-06       Impact factor: 5.157

Review 8.  Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection.

Authors:  Karolina Rembeck; Martin Lagging
Journal:  Pharmacogenomics       Date:  2015-08-07       Impact factor: 2.533

9.  ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.

Authors:  Kei Morio; Michio Imamura; Yoshiiku Kawakami; Takashi Nakahara; Yuko Nagaoki; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Hiroshi Aikata; Clair Nelson Hayes; Grace Naswa Makokha; Hidenori Ochi; Hajime Amano; Keiko Arataki; Takashi Moriya; Hiroyuki Ito; Keiji Tsuji; Hiroshi Kohno; Koji Waki; Toru Tamura; Toshio Nakamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-11-07       Impact factor: 6.772

10.  The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.

Authors:  Bita Behnava; Heidar Sharafi; Maryam Keshvari; Ali Pouryasin; Leila Mehrnoush; Shima Salimi; Pegah Karimi Elizee; Mehran Ghazimoghaddam; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-01-23       Impact factor: 0.660

View more
  1 in total

1.  A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms.

Authors:  Seyed Ehsan Alavian; Heidar Sharafi; Paniz Shirmast; Seyed Moayed Alavian; Bita Behnava; Mohammad Pouryasin; Maryam Keshvari; Ali Pouryasin
Journal:  J Clin Lab Anal       Date:  2018-04-16       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.